-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$38.004.91% Upside
Supernus Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. has been rated by research analysts at Piper Sandler, Jefferies, Stifel Nicolaus in the past 90 days.